Abstract
Over the last couple of years, biotechnology has been giving many leads in different areas of production. In the pharmaceutical industry, it has led to many discoveries and innovations by birthing vaccines, killing microbes using antibiotics and developing many products of pharmaceutical importance. Having served and still serving as an alternative to the chemical approach of drug discovery and development in pharmacy, it is conspicuous that the application of biotechnology in the production and development of biopharmaceuticals could serve as a breakthrough in the development of novel pharmaceuticals. This paper aims to (i) identify and shed light on certain areas which are currently posing a threat to the development and use of biopharmaceuticals and those which may likely have a crippling effect on biopharmaceuticals in the future (ii) suggest and/or provide solutions to these problems, and (iii) identify promising areas for subsequent researches on the seemingly vast benefits of biotechnology in modern healthcare.
Keywords: Biopharmaceuticals; Biotechnology; Anti-drug Antibody; Healthcare
References
- Hu H and Chung CC. “Biopharmaceutical Innovation System in China: System Evolution and Policy Transitions (Pre-1990s-2010s)”. Int J Health Policy Manag 4.12 (2015): 823-829.
- Wang B., et al. “Model-Based Discovery and Development of Biopharmaceuticals: A Case Study of Mavrilimumab”. CPT Pharmacometrics Syst. Pharmacol 7 (2018): 5-15.
- Ebbers HC., et al. “The Role of Periodic Safety Update Reports in the Safety Management of Biopharmaceuticals”. Eur J Clin Pharmacol 69 (2013): 217-226.
- International Conference on Harmonisation (ICH). E2C(R1): Clinical Safety Data Management: Periodic Safety Update Reports for Marketed Drugs. ICH, Geneva (2005).
- International Conference on Harmonisation (ICH). Final concept paper periodic safety update reports for marketed drugs. E2C(R2) and gap and potential improvement analysis of ICH E2C, E2E and E2F ICH, Geneva (2010).
- Rathore AS., et al. “Role of Knowledge Management in Development and Lifecycle Management of Biopharmaceuticals”. Pharm Res 34 (2017): 243-256.
- Rathore AS and Winkle H. “Quality by Design for Biopharmaceuticals”. Nat Biotechnol 27.1 (2009): 26-34.
- Torkko M., et al. “The Utilization of Quality KPIs in the Pharmaceutical Industry”. J Pharm Innov 9.3 (2014): 175-82.
- Long Z and Mao J. “Research on the Listed Pharmaceutical Manufacturing Companies Performance Evaluation System”. In: Qi E, Shen J, Dou R, editors. The 19th international conference on industrial engineering and engineering management. Berlin Heidelberg: Springer (2013): 165-73.
- Gunn III GR., et al. “From the Bench to Clinical Practice: understanding the challenges and uncertainties in immunogenicity testing for biopharmaceuticals”. Clinical and Experimental Immunology 184.2 (2016): 138-46.
- Gallucci S and Matzinger P. “Danger Signals: SOS to the Immune System”. Curr Opin Immunol 13 (2001): 114-9.
- Schellekens H and Casadevall N. “Immunogenicity of recombinant human proteins: causes and consequences”. J Neurol 251.suppl.2 (2004): 114-9.
- Li J., et al. “Detection of low-affinity anti-drug antibodies and improved drug tolerance in immunogenicity testing by Octet ((R)) biolayer interferometry”. J Pharm Biomed Anal 54 (2011): 286-94.
- Lofgren JA., et al. “Comparing ELISA and surface plasmon resonance for assessing clinical immunogenicity of panitumumab”. J Immunol 178 (2007): 7467-72.
- Jahn EM and Schneider CK. “How to systematically evaluate immunogenicity of therapeutic proteins regulatory conditions”. N Biotechnol 25 (2009): 280-6.
- Klee GG. “Human anti-mouse antibodies”. Arc Pathol Lab Med 124 (2000): 921-3.
- Erickson J., et al. “End-to-end collaboration to transform biopharmaceutical development and manufacturing”. Biotechnol Bioeng 118 (2021): 3302-3312.
- Schaber SD., et al. “Economic analysis of integrated continuous and batch pharmaceutical manufacturing: A case study”. Industrial and Engineering Chemistry Research 50.17 (2011).
- Khanal O and Lenhoff AM. “Developments and opportunities in continuous biopharmaceutical manufacturing”. MABS 13.1 (2021): 1903664.
- Rathore AS and Shareef F. “The influence of domestic manufacturing capabilities on biologic pricing in emerging economies”. Nat Biotechnol 37.5 (2019): 498-501.